Skip to content
Company Analysis

Edwards Lifesciences Corporatio EW

A comprehensive view of key metrics, scores, and financial health for Edwards Lifesciences Corporatio

Overview of Edwards Lifesciences Corporation

EW NYQ
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Large Cap
Edwards Lifesciences Corporation (EW), is a Large Cap company, in the Medical Devices industry, last closed at $86.72, about 78.8% overvalued vs fair value, +11.8% 1Y return, placing in the top 25% of its sector.
Metrics P/E 46.5× Rev Growth 11.6% ROE 10.6% Gross Margin 78.0%
USD 86.72
-3.54%
(Delayed)
• Vol 90d: 26.7%
52-Week Range
Market Cap
$52.59B
Enterprise Value
$50.39B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Excellent
Health
Fair
Efficiency
Weak
Valuation
Good
Growth
Fair
Profitability
Excellent
Health
Fair
Efficiency
Weak
Valuation
Good
Completeness: 100%
Confidence: 63%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.edwards.com
HQ Irvine, CA
Employees 16,000
Fiscal year Dec 31

Next Events

Earnings Oct 29 Estimated

Fair Value Snapshot

Bear Base Bull
$16
$18
$21
Current: $86.72 -79% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$6.1B
11.5%%
Gross Profit
$4.7B
9.5%%
Operating Income (GAAP)
$1.6B
10.5%%
EBITDA
$1.4B
-15.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
78.0%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Edwards Lifesciences Corporatio's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
77
/100
Strong
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.87). This signals strong consumable attach-rate economics.
  • Superior Capital Returns Capital return quality is top-tier (score 0.82). High ROIC indicates the business is reinvesting at attractive rates.

Key risks

  • Operating Margin Compression Operating margin trend is negative (score 0.28). Sustained compression would reduce the commercial moat.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
76
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing EW's balance between Growth (20.5%), Profitability (41.6%), and Safety (37.9%). Growth 20% Safety 38% Profitability 42%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

44th percentile vs peers
45
Key Signals
Rev Growth YoY 11.6% 62p Revenue CAGR 3Y 10.8% 60p EPS CAGR 3Y -9.1% 25p Asset Growth YoY 4.9% 61p EPS Growth YoY -73.7% 12p
Strengths
  • Gross Profit Margin in top 20% of peers (78.0%, 86th percentile)
  • FCF Margin in top 20% of peers (22.0%, 94th percentile)
  • Operating Margin in top 20% of peers (27.0%, 95th percentile)
Risks
  • EPS Growth YoY in bottom 20% of peers (-73.7%)

Profitability

90th percentile vs peers
91
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

82th percentile vs peers
83
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Edwards Lifesciences Corporatio.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$18.40
- - -
-78.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000